Pinnacle Medicines | $89,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
Mirage | $75,000,000 | (Mar 27, 2026)
Certified by Founder
Lodge
HI-Bio
start up
United States
- South San Francisco, California
- 05/01/2024
- Series B
- $95,000,000
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
- Industry Biotechnology Research
- Website https://hibio.com/
- LinkedIn https://www.linkedin.com/company/hibio/about/
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)
Payy | $6,000,000 | (Mar 27, 2026)
Conntour | $7,000,000 | (Mar 27, 2026)
KilgourMD | Undisclosed Amount | (Mar 27, 2026)
Terrestrial | $50,000,000 | (Mar 27, 2026)
Krane | $9,000,000 | (Mar 26, 2026)
Zalos (YC F25) | $3,600,000 | (Mar 26, 2026)